Metastatic Breast Cancer

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with HER2-low breast cancer.

CHICAGO — Healio spoke with Nikhil Wagle, MD, about his educational session on the role genomic profiling and treatment decisions in metastatic breast cancer at ASCO Annual Meeting.

Combination therapies appeared associated with better outcomes than monotherapies for treatment of hormone receptor-positive, ERBB2-negative metastatic breast cancer, according to study results published in JAMA Network Open.

Eleanora Teplinsky, MD (@drteplinsky). June 5, 2022. Standing ovation for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22. [Video in original post.] Twitter.

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.

Most Black patients with cancer reported a somewhat or very high likelihood of considering clinical trial participation, yet many had not been informed of the opportunity to enroll onto a clinical trial, study results showed.

The FDA granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for treatment of adults with unresectable or metastatic HER2-low breast cancer, according to a press release from the agent’s manufacturer.

Liquid biopsy — once just a promising technology — is now an important tool for selecting treatment for certain patients with breast cancer, according to Melissa McShane, MD.

The FDA granted fast track designation to Bria-IMT, an investigational cell-based therapy for the treatment of women with metastatic breast cancer.